Jonathan Zung, PhD

  • Group President, Clinical Development & Commercialization Services

Dr. Zung is group president, Clinical Development & Commercialization Services for Covance Drug Development. He joined Covance in April 2016.

A member of the Covance Global Operating Committee, Dr. Zung is responsible for overseeing Early Clinical Services, Phase II-IV Clinical Development and Market Access Services. He is a proven R&D leader with more than two decades of biopharmaceutical experience in all phases of drug development. He has led major development projects in oncology, immunology, cardiovascular diseases, central nervous system diseases and virology.

Prior to joining Covance, Dr. Zung was vice president and head of Global Clinical Sciences and Operations at UCB, a global biopharmaceutical company and leader in developing treatments for severe diseases of the immune and central nervous systems. In this capacity, he was responsible for clinical operations, data management, statistical sciences, contracting, medical writing and operational excellence. Prior to UCB, Jonathan was vice president and head of Global Development Operations at Bristol-Myers Squibb, where he led a 1,400-person organization that managed clinical trials from Phase II through registration. Dr. Zung also held several positions of increasing responsibility at Pfizer Global Research and Development.

Dr. Zung currently is a member of the board of directors of the Clinical Data Interchange Standards Consortium. Previously, he served as chair of the TransCelerate BioPharma operations committee from 2013-2015 and served as a member of The Florida Institute of Technology Board of Trustees from 2010- 2016.

He received his doctorate in analytical chemistry from Emory University in Atlanta, Georgia and has a bachelor’s degree in chemistry from the Florida Institute of Technology in Melbourne, Florida.